Rapid Dose talks QuickStrip research

Executive Summary

• Rapid Dose Therapeutics provided an update on its cannabinoid research and the clinical evaluation of its proprietary QuickStrip oral thin film delivery platform.
• Independent research led by the University of Regina and University of Saskatchewan is examining naturally produced cannabinoids for pain management and neuroprotection in contact sports, supported by NFL grant funding.
• A clinical study initiated in Q2 2024 is evaluating the bioavailability of CBD delivered via QuickStrip compared to traditional oral formats; over 60% of raw data has been extracted, with remaining enrollment expected in Q2 2026.

Key Details

• Research Partnership: Independent research conducted by Dr. Patrick Neary (University of Regina) and Dr. Jane Alcorn (University of Saskatchewan) focuses on naturally produced cannabinoids for pain management and neuroprotection related to concussion and contact sports.
• Funding Source: The research program is supported by grant funding from the National Football League (NFL).
• Clinical Study Status: A separate clinical study arm, initiated in Q2 2024, is assessing the bioavailability and absorption efficiency of CBD delivered via QuickStrip versus standard oral forms.
• Data Extraction: Raw data has been extracted for over 60% of enrolled participants to date.
• Enrollment Timeline: Enrollment of remaining participants is expected to continue in Q2 2026.
• Stability Studies: Real-time and accelerated stability studies of the CBD QuickStrip investigational product are continuing in parallel.
• Strategic Validation: The company states these initiatives validate the QuickStrip platform's potential for pharmaceutical and wellness applications, emphasizing rapid, discreet, and efficient delivery.

Notable Quotes

• "The study is designed to assess absorption efficiency by measuring how much CBD moves through the body and how long it stays there after each type of product, we can determine whether the strips deliver CBD more efficiently than the standard oral form," said Dr. Alcorn.